# Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

> **NCT07214688** · PHASE2 · RECRUITING · sponsor: **Hackensack Meridian Health** · enrollment: 209 (estimated)

## Conditions studied

- Allogeneic Stem Cell Transplant Recipient

## Interventions

- **DRUG:** Fludarabine
- **RADIATION:** Intermediate-dose Total Body Irradiation (TBI)
- **DRUG:** Post-transplant Cyclophosphamide (PTCy)
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate mofetil (MMF)

## Key facts

- **NCT ID:** NCT07214688
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-06
- **Primary completion:** 2032-01
- **Final completion:** 2032-01
- **Target enrollment:** 209 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07214688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07214688, "Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07214688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*